CsA, FK506, corticosteroids and rapamycin inhibit TNFα production by cultured PTEC  by Yard, Benito A. et al.
Kidney International, Vol. 44 (1993), pp. 352—358
CsA, FK506, corticosteroids and rapamycin inhibit TNFa
production by cultured PTEC
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CsA, FK506, curticosteroids and rapainycin inhibit TNFa production
by flEC. In this study we investigated the effect of immunosuppressive
drugs on the interleukin-1 alpha (IL-la) enhanced tumor necrosis factor
alpha (TNFa) production by proximal tubular epithelial cells (PTEC),
Under basal conditions cultured PTEC produce between 0 to 390
pg/mi/b5 cells of TNFa. Upon stimulation with IL-la an enhancement
of TNFa production was seen in each cell line tested, ranging from 230
to 2424 pg/ml/105 cells. The presence of cyclosporin A (CsA) during
stimulation with IL-l a inhibited the enhanced TNFa production in a
dose dependent fashion, with a maximal inhibition of 90% at a concen-
tration of 250 ng/ml. Inhibition was at the level of mRNA as could be
demonstrated by Northern blot analysis. FK506, corticosteroids and
rapamycin also inhibited TNFa production in a dose dependent fashion,
although not as effectively as CsA. Two corticosteroids were tested for
their inhibitory effect on TNFa production. It was found that dexa-
methasone at a concentration of 10 ng/ml inhibited TNFa production
for almost 40%. A 100-fold higher concentration of hydrocortisone was
necessary to yield similar inhibition. The effect of rapamycin on the
IL-la enhanced TNFa production differed from the effect of CsA.
While CsA induced a maximal inhibition of 90%, rapamycin only
induced a maximal inhibition of 37%, and even less inhibition at higher
concentrations of the drug. The presence of the various drugs was
essential for their inhibitory effect, because removal of the drug from
the PTEC by washing immediately resulted in loss of inhibition.
Combinations of CsA and FKSO6 or rapamycin were not additive.
However, combinations of rapamycin and FK506 were antagonistic
when low concentrations of rapamycin and FK506 were used. Low
concentrations of rapamycin with high concentrations of FK506 were
synergistic. Since TNFa is likely to be an important mediator in renal
allograft rejection, these data suggest that the beneficial effect of
immunosuppressive drugs after renal transplantation may partly be due
to the effect on TNFa production by renal parenchymal cells.
Tumor necrosis factor alpha (TNFa), a cytokine primarily
produced by monocytes, tissue macrophages and a variety of
other cell types, plays an important role in microbial infection,
tissue injury and inflammatory disease [11. It has been reported
recently that TNFa may also function as a costimulatory factor
for T cells in non-pathological conditions [2, 3]. TNFa has a
pleiotrophic effect on the immune system and its production is
tightly regulated under normal conditions [4—7].
In studies of Kelley et a! [8—10] it became apparent that
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murine renal tubular cells can act as immune accessory cells
since they express MHC class II and adhesion molecules. More
recently we have described that cultured human proximal
tubular cells (PTEC) produce TNFa [11].
Immunosuppressive agents have made a significant contribu-
tion to the clinical success of organ transplantation. Four major
immunosuppressants, corticosteroids, cyclosporin A, FK506
and rapamycin, have been described to exert a strong inhibitory
effect on the immune response. These agents interfere with one
or more crucial steps of the immune response. Recently we
have shown [11] the presence of TNFa in biopsies of rejecting
human renal allografts, both in the mononuclear cell infiltrate
and on proximal tubuli, suggesting a local role for TNFa in the
ongoing immune response in the kidney. Our objective for this
study was to investigate whether corticosteroids, CsA, FK506
and rapamycin exert their beneficial effect after renal transplan-
tation partly by inhibition of TNFa production by renal paren-
chymal cells. To this end PTEC lines cultured from 14 biopsies
were investigated for their capacity to produce TNFa in vitro.
The effect of immunosuppressive agents on TNFa production
by PTEC is reported in this paper.
Methods
Cell culture procedure
Fourteen PTEC lines were established following the methods
described by Detrisac et al [12]. PTEC were cultured in
serum-free Dulbeco's modified Eagle's medium DMEM and
Ham's F12 medium in a 1:1 ratio (Seromed Biochrom KG,
Berlin, Germany). The medium was supplemented with insulin
(S .rg/ml), transferrin (5 p.glml), selenium (5 ng/ml), hydrocor-
tisone (36 nglml), tri-iodothyronine (4 pg/ml) and epidermal
growth factor (10 ng/m!) (all from Sigma Chemical Co., St.
Louis, Missouri, USA). Cells were grown on a matrix of bovine
collagen (Vitrogen Collagen Corporation, Palo Alto, California,
USA) and fetal calf serum proteins. For all experiments cells
were used that had been passaged four times. Characterization
of these cells as PTEC was done on the basis of staining with
anti-epithelial membrane antigen (EMA, Dako Glostrup, Den-
mark) and four MoAb directed against the adenosine-deaminase
binding protein (provided by Dr. Dinjens, University Hospital,
Maastricht, Germany; Fig. I). No contaminating CDl4 mono-
cytes or macrophages were present in the PTEC cultures. All
PTEC lines were derived from biopsies before transplantation.
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Fig. 1. Immunofluorescence staining of cultured PTEC. A. Negative control (OKT3, ascites dilution 1:500). B. Anti-CD14 (ascites dilution 1:500).
C. Anti-EMA (dilution 1:100) and D. Anti-deaminase binding protein (1071, hybridoma supernatant dilution 1:2).
HLA typing of the donor was provided by Dr. F. Claas
(Department of Immunohaematology, University Hospital Lei-
den, The Netherlands). Sex, age and HLA typing of donor-
derived PTEC lines are given in Table 1.
Immunosuppressants
In this study the following immunosuppressants were used:
cyclosporin A (Sandoz Basle, Switzerland), FK506 (a gift from
Dr. Murato (Fujisawa Pharmaceutical Company, Osaka, Ja-
pan), dexamethasone, hydrocortisone (both from Sigma) and
rapamycin (Wyeth-Ayerst, Rouses Point, New York, USA).
Treatment with inzmunosuppressants and IL-I a stimulation
PTEC were seeded in 24 well plates (Costar, Cambridge,
Massachusetts, USA) at a concentration of l0 cells/well in
culture medium without hydrocortisone. After a period of 24
hours PTEC were stimulated with IL-i a in the presence or
absence of various immunosuppressants. Duration of immuno-
suppressive treatment was variable, depending on the question
asked in a particular experiment. In every case after ending the
experiment cells were recovered from the wells, counted and
viability was determined using trypan blue exclusion. All ex-
perimental conditions were performed in duplicate.
Determination of TNFa production
TNFa activity in culture supernatants was measured in a
standard cytotoxicity assay using L929 fibrosarcoma cells
(ATCC, Rockville, Maryland, USA) as has been described
previously [13]. Briefly, 2.5 x i05 cells/ml in medium containing
1 j.g/ml of actinomycin D (Sigma) were plated in 96-well flat
bottom plates (Costar) to which supernatants were added in
triplicate. Plates were incubated for 18 to 24 hours at 37°C.
Thereafter plates were washed with phosphate buffered saline
(PBS) and viable cells were stained with Crystal violet for 15
minutes. After washing three times with PBS 100 d of 1% SDS
was added to each well. Optical densities were measured on a
96-well microtiter plate reader at 590 nm. Serial dilutions of
human recombinant TNFa (1.6 to 1660 pg/ml) in the presence or
absence of IL- 1 a were used to produce standard curves (Fig. 2).
In all cases cytotoxicity against L929 cells could be blocked by
treating the supernatants with a polyclonal anti-TNFa antibody
[111.
RNA preparation and Northern blot analysis
Total RNA was isolated from confluent monolayers of cul-
tured PTEC with a single-step guanidium isothiocyanate-phe-
nol-chloroform extraction [14]. An equal amount of total RNA
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Table 1. Production of TNFa in the presence or absence of IL-la by
PTEC lines obtained from 14 different donors
Cell
line
Donor
age°/
sex" HLA
TNFa production
pg/mF
IL-la
Medium I ng/ml
1 21/M A2A987D18DR2 6612d 816±16
2 4l/M A3B7DR2 126±18 691±32
3 43/M A2 A3 B7 B16 DRI
DR2
120 31 516 17
4 41/F A2 A28 Bl2 B16 DR4 390 12 2424 29
5 56/M A2 B7 B17 DR4 DR7 0 636 32
6 23/F A2 A28 B44 B12 DR4
DR12
120 11 579 63
7 19/F A3 A23 B44 B35 DR1
DR7
0 230 47
8 34/M A1A3B8DR3DR7 0 436±16
9 20/F A2 A9 B5 B8 DR5 DR7 153 16 233 21
10 18/M Al A3 B14 B37 DR3
DR4
65 18 696 42
11 36/F A3A11B7DR2 88±20 1694±73
12 28/M A2 B5 B51 B40 DRW6
DRWI3
128 104 1210 166
13 37/M Al AW19 B8 B14 DR1 0 816 83
14 34/F A1A2B7B8DR2DR5 160±57 2126± 104
a Age in years
"Male (M), Female (F)
TNFa production by PTEC was assessed after 18 hours of incuba-
tion with culture medium alone or culture medium supplemented with
IL-la as described in the Methods
d Data represent mean production sD/b5 cells of quadruplicate
determinations
(25 Mg) was loaded on a 1.2% agarose gel, electrophorsed under
denaturating conditions and transferred onto nylon membranes
(ICN, East Hills, New York, USA). Blots were baked at 80°C
to cross-link RNA to the blot. Prehybridization was performed
using a mix of Sx Denhardt's, 5x SSC, 50 mst NaH2PO4 (pH
6.5), 0.1% sodium dodecyl sulfate (SDS), 250 j.tg/ml herring
sperm DNA and 50% formamide, for two to four hours at 42°C.
A specific 820 kb cDNA encoding human TNFa and a specific
cDNA encoding /3 actin were isolated from pUC 19 (provided
by Dr. P. van der Elsen, Dept. of Immunohaemotology, Lei-
den, The Netherlands) by plasmid digestion with EcoRl
(Promega, Leiden, The Netherlands). The cDNA probes were
radiolabeled by primer extension using random hexanucleotides
[15]. Blots were hybridized for 16 to 24 hours at 42°C. After
washing twice with 2 x SSC/0. 1% SDS at room temperature and
twice with 0.1 x SSC/0. 1% SDS at 50°C the blots were exposed
to Kodak X-AR film at —70°C for seven days.
Results
Heterogenicity in TNFa production by cultured PTEC
In this study the production of TNFa by 14 different PTEC
lines was examined both under unstimulated and stimulated
(IL-la 1 ng/ml) conditions. As reported before [11], there was a
clear heterogenicity in TNFa production by these lines ranging
from 0 to 390 pg/ml/105 cells. In every case an increase in TNFa
production, ranging from 230 to 2424 pg/m11105 cells, was seen
upon stimulation with 1 ng/ml of IL-la. No correlation was
found between the basal production and percent increase in
TNFa production (Table 1). TNFa was de novo synthesized
10 100 1000 10000
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Fig. 2. Representative standard curves of the TNFa L929 assay in the
absence (—0—) or presence (——) ofIL-la.
since treatment with cycloheximide reversibly abolished its
production [11]. There was no relation between HLA DR2
positivity and the amount of TNFa produced by cultured PTEC
[DR2— mean 112 (N = 5); range 66 to 160 pg/mI/b5 cells vs.
DR2+ mean 93 (N = 9); range 0 to 390 pg/ml/l05 cells; Table 1].
IL-i a had no effect on the L929 cytotoxicity as could be seen
from the standard curves performed in the presence or absence
of IL-la (Fig. 2). In addition the presence of an anti-IL-la
MoAb did not influence TNFa determinations (data not
shown).
Effects of immunosuppressive drugs on IL-la enhanced
TNFa production
To examine the effect of the different immunosuppressive
drugs on IL-la enhanced TNFa production, PTEC were cul-
tured in the presence or absence of these drugs together with
IL-l a (1 ng/ml) for 24 hours.
It was found that CsA inhibited IL-la enhanced TNFa
production in a dose dependent fashion. Maximal inhibition was
achieved with 250 ng/ml of CsA (Fig. 3). Further experiments
were performed using this concentration, since it appeared to
be optimal for inhibition. Upon stimulation with IL-la an
enhanced production was observed with all PTEC lines studied.
CsA at a concentration of 250 ng/ml administered at various
time intervals after stimulation with IL-la, inhibited further
production of TNFa (Fig. 4). Preincubation with CsA (250
ng/ml) and removal of the drug by intensive washing of the cells
before stimulation failed to inhibit TNFa production, showing
that CsA must be present to exert its inhibitory effect. To
investigate whether inhibition of TNFa production was due to a
decreased mRNA for this cytokine, Northern blot analysis was
performed. Total RNA was extracted from unstimulated or
IL- 1 a (1 ng/ml) stimulated PTEC in the presence or absence of
CsA (250 ng/ml). Using a specific probe for TNFa, a 2.0 kb
hybridization signal was found in unstimulated conditions and
an increased signal was found upon IL-la stimulation. How-
ever, upon treatment with CsA no hybridization signal was
found even after IL-la stimulation (Fig. 5).
1 1
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Fig. 3. Dose-dependent inhibition by CsA of IL-la enhanced produc-
tion of TNFa by cultured human PTEC. Cells (105/well) were plated in
24 well plates and cultured for 24 hours. Duplicate wells were then
stimulated with IL-la (1 ng/ml) in the presence of increasing concen-
trations of CsA (•) or the vehicle (0) for 18 hours. Thereafter the
supernatants were harvested and assessed for TNFa. Percentage inhi-
bition was calculated by taking the IL-i a stimulated condition in the
absence of CsA or the vehicle as maximal TNFa production.
Time, hours
Fig. 4. Inhibition of TNFa production by CsA after the onset of iL-la
stimulation. PTEC were cultured with IL-la (1 ng/ml) and at various
time points assessed for TNFa (0). Also at 0, 2 and 4 hours after the
start of the experiment 250 nglml of CsA was added to the cultures.
TNFa production was assessed 24 hours after the start of the experi-
ment (•). All conditions were tested in duplicate and the results are
presented as the mean of these values.
IL-i a enhanced production of TNFa by cultured PTEC was
also inhibited by other immunosuppressive drugs. FK506 inhib-
ited TNFa production in dose dependent manner with maximal
inhibition of 45% at a concentration of 100 ng/ml (Table 2).
Preincubation of PTEC with FK506 for 24 hours followed by
washing of the cells and subsequent stimulation with IL-i a had
no inhibitory effect.
In addition to FK506 two corticosteroids, that is, hydrocor-
tisone and dexamethasone, were tested for their inhibitory
effect on IL-i a enhanced TNFa production by PTEC. Dexa-
methasone was a much more potent inhibitor of TNFa produc-
tion in comparison to hydrocortisone. Maximal inhibition of
Fig. 5. Northern blot analysis of total RNA isolated from unstimulated
or IL-la (1 ng/ml) stimulated PTEC in the presence or absence of CsA
(250 ng/ml). For each preparation 20 g of RNA was loaded on a 1.2%
agarose gel and electrophoresed. Thereafter RNA was blotted to a
nylon membrane and hybridized to a specific TNFa probe (A) and f3
actin probe. B. The agarose gel stained with ethidium bromide before
the blotting procedure.
40% was already seen with 10 ng/ml of dexamethasone,
whereas a similar inhibition was seen with hydrocortisone at a
concentration of 1 g/ml (Table 2). Pretreatment of PTEC with
these corticosteroids at concentrations to give maximal inhibi-
tion and removal of these drugs before stimulation with IL-i a
did not inhibit enhanced TNFa production. Finally, the effect of
rapamycin on IL-la enhanced TNFa production was tested. A
dose dependent inhibition of TNFa production by rapamycin
was observed reaching a maximal inhibition of 37% at a
concentration of 10 nglml. At higher concentrations, however,
less and no inhibition were observed (Table 2). All immunosup-
pressive drugs used at the highest concentration were not
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Table 2. Effects of FK506, hydrocortisone, dexamethasone and
rapamycin on the IL-la enhanced TNFa production by PTEC
Immunosuppressive drug % Inhibitiona
FK506 ng/ml
0 0
1 15±4
10 29±7
50 37±6
100 45±6
250 43±3
Hydrocortisone p.g/rnl
0 0
0.05 9±4
0.1 25±7
1 39±6
Dexamethasone ng/ml
0 0
5 15±3
10 40±6
100 38±6
Rapamycin nglml
0 0
0.1 7±3
1 --.'
10 —-
100 24±4
250 3±3
a Calculated by taking the IL-la stimulated condition as 100% of
TNFa production; data represent mean % inhibition SD of quadru-
plicate determinations
cytotoxic for PTEC based on trypan blue exclusion. In addition
the effect of all immunosuppressive drugs tested were revers-
ible, since after removal of the drug PTEC responded to IL-i a
in a normal fashion (Fig. 6).
To test whether different immunosuppressive drugs had
additive or synergistic effects experiments were carried out
using different combinations of drug treatment of PTEC. An
additive effect was seen when either combinations of FK506
and CsA or combinations of CsA and rapamycin were tested
(Tables 3 and 4). However, combinations of FK506 and rapa-
mycin differentially influenced inhibition of TNFa production
by PTEC. A low dose of rapamycin (10 nglml) inhibited TNFa
production for 49% (Table 5). Together with a low dose of
FK506 (1 nglmi) an antagonistic effect was seen resulting in less
inhibition of TNFa production. Rapamycin used in a dose of 10
nglrnl together with high concentrations of FKSO6, however,
resulted in a synergistic effect. A high dose of rapamycin (250
ng/ml) did not inhibit TNFa production. In combination with a
low dose of FK506 1 ng/ml, a 47% inhibition of TNFa produc-
tion was seen. In contrast, combinations of a high dose of
rapamycin together with high concentrations of FK506 did not
inhibit TNFa production.
Discussion
In this study we investigated the effect of immunosuppressive
drugs on IL-i a enhanced TNFa production by cultured human
PTEC. A heterogeneous production of TNFa was observed in
14 established PTEC lines. Production of TNFa was always
enhanced upon IL- 1 a stimulation; the amount of basal TNFa
production was not related to the increase seen after IL-i a
stimulation (Table 1). These results are compatible with previ-
ous studies reporting on the production of TNFa by human [11]
and murine [16] tubular cells. It has been shown by Jacob et al
[17] and Bendtzen et al [18] that monocytes or macrophages
from DR2+ individuals produce statistically less TNFa upon
LPS stimulation. Since the TNFa gene is found within the
MHC locus, it has been suggested that low production of TNFa
may be due to the expression of certain DR allotypes. In our
study there were 14 PTEC lines from different individuals. No
relation was found between DR2 positivity and the amount of
TNFa produced.
Immunosuppressive drugs have been shown to exert their
beneficial effect mainly by preventing activation of T cells
[19—21]. Inhibition of the production of cytokines has been
suggested as a mechanism for preventing activation of T cells.
The effect of CsA, FK506, corticosteroids and rapamycin on
the IL-i a enhanced production of TNFa was examined in this
study. It was found that CsA inhibited TNFa production by
cultured PTEC in a dose dependent fashion (Fig. 3). Maximal
inhibition was seen at a concentration of 250ng/ml correspond-
ing to 90% inhibition. When cultured PTEC are stimulated with
1 nglml of IL-I a and subsequently CsA (250 ng/ml) is adminis-
tered at various time intervals, further TNFa production is
inhibited (Fig. 4). By Northern analysis we found less TNFa
mRNA isolated from PTEC treated with CsA even after stim-
ulation with IL-la, whereas mRNA for 13 actin was the same,
suggesting that CsA interferes with the generation of TNFa
mRNA. Several reports have documented that CsA inhibits the
production of IL-2 by T lymphocytes by inhibiting specific
mRNA synthesis [19, 22, 23]. Additional work showedthat CsA
down-regulates IL-4 and gamma IFN, also at the level of
mRNA [241. In other studies by Nguyen et al [25] it has been
shown that CsA inhibits TNFs production but not TNFa
mRNA in monocytes of CBA/J mice. This suggests that TNFa
expression regulation differs between PTEC and monocytes.
Previously we have shown [11] that LPS stimulated PTEC do
not produce TNFa, which is in contrast to the monocytes
reported by Nguyen et al [25]. Alternatively, a low TNFa
mRNA signal after CsA treatment could be explained by a more
rapid breakdown of the specific mRNA. Instability of mRNA
coding for cytokines has been reported for those mRNA's
containing AU-rich sequences in the 3' untranslated region [26,
27]. The results of this study are compatible both with inhibited
production and or increased breakdown of TNFa mRNA after
CsA treatment.
Other immunosuppressive drugs also appeared to inhibit
TNFa production by cultured PTEC in a dose dependent
fashion. FKSO6, corticosteroids and rapamycin were less potent
inhibitors of TNFa production in comparison to CsA. Two
corticosteroids were tested and it was found that dexametha-
sone inhibited TNFa production for 40% at a concentration of
10 nglml, whereas a 100-fold higher concentration of hydrocor-
tisone was necessary to yield similar inhibition. Rapamycin had
a differential effect on TNFa production depending on the dose
used. Concentration between 0.1 and 10 ng/ml gave an inhibi-
tory effect in a dose dependent fashion. However, 100 ng/ml
was less inhibitory than 10 nglml and 250 ng/ml was not
inhibitory at all. None of the tested immunosuppressive drugs
were found to be cytotoxic. Trypan blue exclusion was always
performed after the end of each experiment and was not
different from that of control conditions with a cell viability of
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IL-la, ing/mi
GsA, 250 ng/mI
Hydrocortisone, 1 p.g/mi
Dexamethasone, 10 ng/mi
Rapamycin, 250 ng/mi
Rapamycin, 10 ng/mi
TNFa production, pg/mi
Fig. 6. Reversible inhibition of TNFa
production by various immunosuppressive
drugs. PTEC plated in 24 well plates (l0
cells/well) were stimulated with IL-la in the
presence or absence of various
immunosuppressive drugs. After 24 hours
supernatants were harvested and assessed for
TNFa (hatched bars). Each well was then
washed three times to remove the drug and
the cells were retested for IL-la enhanced
TNFa production. After an additional 24
hours the supernatants were harvested and
assessed for TNFa (open bars). Each
experimental condition was tested in
duplicate; TNFa determinations were done in
triplicate and the results are presented as the
mean SD of these values.
Table 3. Effects of combinations of CsA and FK506 on IL-I a enhanced TNFa production by PTEC
CsA FK506 ng/ml
ng/ml 0 1 10 50 100 250
0 oa 12±5 19±6 27±8 39±7
1 3±7 17±8 19±4 25±3 35±9
10 15±5 24±6 23±7 32±7 41±8
50 34±8 49±13 37±5 41±8 45±6
100 67±5 72±6 69±4 73±6 76±8
250 87±8 92±11 91±6 87±3 89±4
45±5
42±6
47±9
52±4
81±8
85±9
a Data represent mean % inhibition SD of quadruplicate determinations
Table 4. Effects of combinations of CsA and rapamycin on IL-la enhanced TNFa production by PTEC
CsA Rapamycin ng/ml
ng/ml 0 0.1 1 10 100 250
0 oa 7±6 18±4 37±6 27±3
1 3±7 5±6 20±9 34±11 23±12
10 15±5 17±3 23±6 39±7 30±8
50 34±8 32±9 27±8 45±10 33±4
100 67±5 72±3 77±6 77±9 63±8
250 87±8 88±12 85±4 81±9 73±6
2±2
5±3
18±4
29±7
52±8
77±6
a Data represent mean % inhibition SD of quadruplicate determinations
Table 5. Effects of combinations of rapamycin and FK506 on IL-i a
enhanced TNFa production by PTEC
Rapamycin
ng/ml
FK506 ng/ml
0 1 10 100
0 oa 18
7 12 71 68±5
250 3±5 47±8 0 0
a Data represent mean % inhibition SD of quadruplicate determi-
nation
more than 95%. The immunosuppressive drugs did not cause
irreversible damage to the TNFa production capacity of PTEC,
since they responded in a normal fashion to IL-i a after the drug
had removed by washing (Fig. 6). Preincubation studies with all
drugs failed to inhibit TNFa production, suggesting that the
drugs can only exert their inhibitory effect when they are
present during the experiment. Combinations of CsA and
FK506 or CsA and rapamycin were additive. Combinations of
FK506 and rapamycin, however, were at low concentrations of
rapamycin antagonistic with low concentrations of FK506 and
not with high concentrations of this drug. At high concentra-
tions of rapamycin the combination was synergistic with low
concentrations of FKSO6, but at high concentrations of this drug
an antagonistic effect was observed. CsA, FK506 and rapamy-
cm bind to intracellular receptors known as immunophilins [28,
291. Since it has been shown that both rapamycin and FK506
bind to the same immunophilin it was predicted that these drugs
would affect immune cells identically [301. However, it has been
shown in in vitro experiments that these drugs behave quite
differently [281. Recently Thomson [31] reported that FK506
and rapamycin are reciprocal antagonists when applied in a
lymphocyte proliferation assay. A concentration of 10 to 100
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times the effective drug concentration of either agent is required
for inhibition of the other. In an earlier study of Metcalf et al
[32] it was reported that rapamycin and FKSO6 cause antago-
nistic or additive suppression of immune cell activity in vitro. In
this study we found that the effects of low concentrations of
rapamycin could be reversed with low concentrations of FKSO6
but not with high concentrations. This is compatible with the
findings of Metcalf and Richards [32]. Although both these
drugs bind to the same immunophiin, the complex of immuno-
suppressant and immunophiin causes different cellular effects.
This study shows that production of TNFa by cultured
human PTEC is heterogeneous. IL-la enhances TNFa produc-
tion that can be inhibited by the immunosuppressive drugs such
as CsA, FK506, corticosteroids and rapamycin. The beneficial
effect of immunosuppressive drugs after renal transplantation
may therefore partly be attributed to the effect on TNFa
production by renal parenchymal cells.
Reprint requests to B.A. Yard, M.D., Dept. of Nephrology, Univer-
sity Hospital, Building I c3-p, Rzjnsburgerweg 10, 2333 AA Leiden, The
Netherlands.
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